{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Murphy B"],"funding":["National Institute of Neurological Disorders and Stroke","National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","W.W. Smith Charitable Trust","National Cancer Institute","NINDS NIH HHS","NCI NIH HHS","National Institutes of Health","Department of Defense","NIH HHS","Japan Society for the Promotion of Science"],"pagination":["e20231967"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11586802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["221(12)"],"pubmed_abstract":["Patients with metastatic ovarian cancer (OvCa) have a 5-year survival rate of <30% due to the persisting dissemination of chemoresistant cells in the peritoneal fluid and the immunosuppressive microenvironment in the peritoneal cavity. Here, we report that intraperitoneal administration of β-glucan and IFNγ (BI) induced robust tumor regression in clinically relevant models of metastatic OvCa. BI induced tumor regression by controlling fluid tumor burden and activating localized antitumor immunity. β-glucan alone cleared ascites and eliminated fluid tumor cells by inducing intraperitoneal clotting in the fluid and Dectin-1-Syk-dependent NETosis in the omentum. In omentum tumors, BI expanded a novel subset of immunostimulatory IL27+ macrophages and neutralizing IL27 impaired BI efficacy in v"],"journal":["The Journal of experimental medicine"],"pubmed_title":["Myeloid activation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer."],"pmcid":["PMC11586802"],"funding_grant_id":["R50 CA211199","P30 CA010815","202360517","P50 CA228991","S10 OD030244","1R37CA280869","C2205","R21 CA259240","P50CA228991","K99 AI151198","R01 NS131912","R37 CA280869","T32 CA009171","1R01NS131912","1R21CA259240","R21 AI175738","P30CA010815","5R21AI175738","HT94252410206","K99AI151198"],"pubmed_authors":["Nefedova Y","Hamada K","Zhang N","Huang L","Zhang R","Murphy B","Claiborne DT","Kannan T","Veglia F","Miyamoto T","Zhu YP","Mirji G","Kossenkov A","Ugolini A","Manning BS","Shinde R"],"additional_accession":[]},"is_claimable":false,"name":"Myeloid activation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer.","description":"Patients with metastatic ovarian cancer (OvCa) have a 5-year survival rate of <30% due to the persisting dissemination of chemoresistant cells in the peritoneal fluid and the immunosuppressive microenvironment in the peritoneal cavity. Here, we report that intraperitoneal administration of β-glucan and IFNγ (BI) induced robust tumor regression in clinically relevant models of metastatic OvCa. BI induced tumor regression by controlling fluid tumor burden and activating localized antitumor immunity. β-glucan alone cleared ascites and eliminated fluid tumor cells by inducing intraperitoneal clotting in the fluid and Dectin-1-Syk-dependent NETosis in the omentum. In omentum tumors, BI expanded a novel subset of immunostimulatory IL27+ macrophages and neutralizing IL27 impaired BI efficacy in v","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-11T05:10:31.13Z","creation":"2026-06-11T03:08:06.641Z"},"accession":"S-EPMC11586802","cross_references":{"pubmed":["39570374"],"doi":["10.1084/jem.20231967"]}}